To examine the specificity of technetium-99m monoclonal antibody (S12) imaging for identifying activated platelets at interventional injury sites in atherosclerotic rabbit arteries, subgroups of unheparinized rabbits (n =39) underwent serial percutaneous transluminal aortic angioplasty (PTA) procedures (with or without intravascular stent placement) followed by in vivo and then ex vivo gamma camera imaging, scanning, and immunoelectron microscopy to determine the intravascular loci of S12 Fab' antibody binding. Despite angiographic vessel patency, image-derived ratios of in vivo S12 binding in injured versus uninjured vascular segments were significantly increased (p<0.05) after one PTA (1.3+±0.17, n=7), PTA twice at 6-week intervals (1.4±0.22, n=7), and PTA plus stent placement (1.6±0.28, n=7) compared with control experiments (1.1+±0.13, n=7). Ex vivo imaging of blood-free excised aortas confirmed S12 localization at PTA (2+0.4, n=3) and PTA plus stent placement (5+±3.8, n=7) sites (both p <0.05 versus controls). S12 antibody uptake decreased significantly (p <0.05) at 1 week after PTA plus stent placement in vivo (1.1±0.10, n=4) and ex vivo (1.6±0.7, n=3). Electron microscopic studies confirmed dense platelet, fibrin, and red blood cell deposition in regions of acute injury, witth endothelial neointimal proliferation at 1 week after PTA. Immunoelectron microscopic studies confirmed specific in vivo S12 binding (22:1 versus nonrelevant IgG) at sites of a-granule GMP-140 expression in activated platelets. Therefore, S12 studies may be useful to localize sites of platelet-derived mitogen release at arterial PTA injury sites. (Circulation 1991;83:224-236) P latelet aggregation and degranulation are frequently implicated in the pathogenesis of acute coronary syndromes such as unstable
angina pectoris and myocardial infarction.'-4 Therapy for these acute ischemic syndromes and for prevention of acute vessel closure after angioplasty includes intravenous nitroglycerin, heparin, and aspirin, all agents with significant antiplatelet effects.4-8 However, antiplatelet and vasodilator drugs have uniformly failed to prevent early (less than 6 months) restenosis after percutaneous transluminal coronary angioplasty (PTCA).9-15 The principal pathogenetic mechanism for premature restenosis after successful angioplasty appears to be platelet activation with release of growth factors716 that cause intimal smooth muscle proliferation,17-21 which vitiates the original PTCA improvement.
One approach to visualizing platelet activity in vascular injury sites has been radionuclide imaging of indium-111-labeled autologous platelets. [22] [23] [24] [25] The usefulness of these studies is compromised by 1) the need to remove platelets for labeling followed by 30 which is redistributed to the cell surface during fusion of a-granule membranes with the plasma membrane. Therefore, monoclonal antibodies to GMP-140 are specific for and bind only to the surface of stimulated platelets. Imaging studies with radiolabeled polyclonal antibodies to GMP-140 have identified venous thrombi in a baboon model.)
This study was performed to evaluate technetium99m-labeled S12, a monoclonal antibody to GMP-140,27,28 for imaging intravascular platelet-rich thrombi in a graded arterial injury rabbit model. In vivo imaging was correlated with ex vivo imaging, scanning, and immunoelectron microscopic pathological analysis to determine the specificity and loci of antibody uptake.
Methods

Animal Model
The S12-subtype Fab' fragment is cross-reactive with human, nonhuman primate (i.e., baboon), and rabbit platelets but has poor affinity for canine and porcine platelets. Therefore, two rabbit models were developed for these studies.
Adult male New Zealand White rabbits (n=39) weighing [5] [6] [7] [8] [9] [10] levels were significantly elevated in fed animals compared with those of unfed controls (1,277+873 versus 117±91 mg/dl,p<0.01). Animals were sedated with an intramuscular mixture of ketamine (100 mg/ml, 9-ml aliquot; Fort Dodge, Fort Dodge, Iowa), xylazine (100 mg/ml, 0.36-ml aliquot; Haver-Mobay, Shawnee, Kan.), and chlorpromazine (25 mg/ml, 3-ml aliquot; Goldine, Miami, Fla.). Using the Baumgartner technique of atherogenesis,32 balloon endothelial denudation injury of the infrarenal aorta was followed by feeding for a minimum of 4-6 weeks using the atherogenic diet to enhance insudation of cholesterol into the injured arterial segments. This model produced significant atherosclerotic lesions, as shown in Figure 1 . [33] [34] [35] Giant Flemish rabbits (n=4), weighing 15-20 lb (7-10 kg), were used for transluminal extraction catheter (TEC) atherectomy of the carotid arteries. The Baumgartner technique was used to produce typical arteriosclerotic lesions in the midportion of both internal carotid arteries, after which one artery underwent TEC atherectomy, and the other served as the control artery. Other than heparin use in TEC studies, animals were not treated with platelet-inhibiting medications before these or subsequent interventional injury procedures.
Interventional Procedures
Percutaneous transluminal angioplasty. PTA was performed once in seven animals and twice at 6-week intervals in seven rabbits. PTA was performed by either retrograde cannulation of the infrarenal aorta through a contralateral femoral arteriotomy or by selective cannulation of the artery using an over-thewire technique. Standard 3.0-3.5-mm-diameter angioplasty balloon catheters were used (USCI, Billerica, Mass.). After fluoroscopic localization (L1 2 vertebral level), the balloon was hand-inflated to 3-4 atm to overdilate the artery. An Transluminal extraction catheter atherectomy. TEC atherectomy procedures were performed in four rabbits through a femoral arteriotomy incision using a flexible angioplasty guide wire that was fluoroscopically advanced into the right carotid artery. Several integrade passes were made with the TEC along the length of the carotid artery. Contrast angiography of both carotid arteries was performed before and after atherectomy. Technetium-99m S12 Fab' Antibody Radionuclide Imaging
The S12 Fab' antibody fragment was prepared from hybridoma-produced IgG and labeled with 99m Tc using the two-vial kit method of Pak et al. 36 The final specific activity was 20 mCi 9GmTc/mg S12 protein. The incorporation of '9mTc was quantitated by gel-filtration high-performance liquid chromatography equipped with a radiometric detector and instant thin-layer chromatography (Gelman Sciences). Preparations with labeling efficiency of less than 90% were discarded.
Planar anterior-view gamma camera images were acquired using a large field-of-view camera (MEDX 37, Searle) peaked to the 140-kev major energy photopeak of 99mTc (10% window) and a high-resolution parallel hole collimator. Serial studies were acquired every 5 minutes for 1 hour beginning 20 minutes after the ear vein injection of 5 mCi/0.4 mg (400 gg) of G9mTc-labeled S12 antibody injected within 15 minutes of injury. Appropriate shielding of the secondary uptake in background organs, including bladder, kidneys, salivary glands, and thyroid glands, was performed as needed to optimize vascular target counts. In vivo images of the aorta (versus psoas muscle) and carotid (versus sternocleidomastoid muscle) arteries 1 hour after injection had target-to-background ratios averaging 2.9-+±0.9.
A total of more than 400,000 counts (5 minutes) was acquired in in vivo abdominal aortic scintigrams at 1 hour after injection; a total of 10,000 counts (30 minutes) was acquired in ex vivo artery images. A 10-20-,tCi point source was used to define the upper and lower ends of the aorta after ex vivo imaging.
Operator-defined fixed regions-of-interest (ROTs)
were assigned by a blinded experienced nuclear medicine technician to the injured areas of the infrarenal aorta and carotid artery for comparison to uninjured aortic and carotid segments. Counts per pixel in these ROIs were used to generate a ratio of counts in the injured to counts in the uninjured segments-the "injury ratio." An injury ratio of 1.5 indicates a 50% increase of local 99mTc S12 uptake compared with normal blood pool activity. Control animals (without vascular injury) had aortic activity analyzed in vessels of comparable luminal size and anatomical location in an identical fashion to animals undergoing serial PTA and/or stent placement. Briefly, in each animal, the appropriate aortic contrast angiogram was used to assist in the placement of ROls in the upper half and lower half of the infrarenal aorta above the iliac bifurcation. Detailed necropsy dissections were carried out to demonstrate the anatomical location of the infrarenal aorta and iliac arteries to the nuclear technician charged with placing ROIs for the calculation of the injury ratio. If in the opinion of two blinded nuclear physicians, the ROIs selected were incorrectly placed lateral to the aorta, above the renal arteries, or below the aortic bifurcation, the original ROTs were corrected by a consensus of all trained observers. Minimal midline blood pool activity was usually present 1 hour after injection to assist ROI placement. Blood ratio of intimal to medial wall thickness was also derived from each cross section at 70 levels along the length of each vessel. Ultrathin sections of blood clots extracted from the angioplasty-injury regions of the aorta were immunostained with monoclonal S12 antibody and preimmunized rabbit anti-mouse and goat anti-rabbit IgG conjugated with 10 nm colloidal gold.
The rabbit and goat sera were used as the negative control. Known positive controls for the secondary and tertiary antibodies were also carried out.
Statistical Analysis
In vivo and ex vivo imaging data are summarized in Table 1 and are presented as the mean group values + I SD. After the performance of a Wilk-Shapiro test of normality, the mean values (+1 SD) of parametric and nonparametric data for continuous pathology and image-derived parameters were statistically compared using a two-tailed t test. A significance level of a probability value of less than 0.05 was required to reject the null hypothesis. All statistics were performed using commercially available software (RS-1, Bolt Baranek-Newman, Cambridge, Mass.).
Results
In Vivo Imaging Studies
Results of the in vivo S12 Fab' monoclonal antibody imaging studies in all 43 rabbits are presented in Table 1 and Figure 2 . There was no significant difference in the aortic arterial injury ratio between seven unfed and seven cholesterol-fed uninjured control rabbits ( 1.1 ±+0.13 and 1.2 ± 0.13, respectively; p-NS). Figure 3 illustrates in vivo and ex vivo imaging data for a cholesterol-fed control rabbit. 1.57 +0.28) occurred with blood pool clearance in PTA plus stent aortas. These data confirm the qualitative determination that S12 activity at injury sites was best evaluated at 60 minutes.
One week after PTA plus stent placement, the injury ratio had decreased significantly (1.1±0.10, p.< 0.05 versus acute PTA plus stent studies) to values not different from controls. Carotic TEC atherectomy in four heparinized rabbits did not acutely increase S12 antibody uptake in vivo (1.23±0.06), although one rabbit did exhibit increased ex vivo S12 activity ( Figure 5 ).
Ex Vivo Imaging Studies
Arteries from 25 rabbits were excised immediately after completion of in vivo imaging for ex vivo imaging of S12 antibody distribution ( Table 1) . As with the in vivo images, there was no difference between the injury ratios in unfed and cholesterolfed controls (1.0±0.11 versus 1.27+0.5, respectively; p=NS).
Ex vivo S12 activity was increased at single PTA sites (2.1±0.35, n=3, p<0.05 versus controls). PTA plus stent placement (Figure 4) (Figure 1) . Angiograms of these lesions before PTA and stent placement demonstrated diffuse irregularities with focal areas of aneurysmal dilatation in some animals.
Associated with acute PTA plus stent placement were marked endothelial cell loss; plaque fissuring and compression; extensive fibrin, red blood cells, white blood cells; platelet thrombus deposition (Figure 6) ; and no evidence of endothelial regeneration.
Despite histological thrombus deposition at PTA and stent placement sties, all vascular lumens were grossly and angiographically patent.
Optical examination of the inner surface of aortas 1 week after stent placement revealed that all stents were covered by a translucent neointimal membrane (Figure 7) , which was completely covered by endothelial cells with silver staining of cell borders ( Figure   8A ) that averaged 213±1 79 gtm in thickness. The intima-to-media ratio increased to 1.9+±0.92 (p<0.05 versus fed and unfed controls).
Scanning electron microscopy. Scanning electron microscopy of unfed and fed controls demonstrated essentially normal endothelial architecture. Single PTA injury caused extensive endothelial denudation and platelet deposition with polymorphic islands of residual normal endothelium. There was no evidence of medial disruption after PTA, possibly because of the fibrocellular nature of atherosclerotic plaques with minimal calcification in this rabbit model. Stent struts remained essentially free of all cellular deposits acutely; however, interstices between the struts were extensively covered with fibrin strands, :
by guest on April 20, 2017 http://circ.ahajournals.org/ Downloaded from FIGURE 6. Scanning electron microscopy (magnification, x640) demonstrating extensive fibrin, red blood cell, and platelet deposition adherent to a stent strut after acute percutaneous transluminal angioplasty plus stent placement. The technetium-99m S12 in]jury ratio in this aorta was 1.5 in vivo and 2.5 ex vivo.
white and red blood cells, and numerous platelets. One week after PTA plus stent placement, scanning electron microscopy revealed extensive neointima covered nearly completely by endothelial cells with borders outlined by silver deposits demonstrated by electron microscopy ( Figure 8B ). The new endothelial cells were immature, as evidenced by their prominent nuclei, polygonal cell shape, and mosaic growth pattern. There was a complete absence of platelets in the injury site.
Immunoelectron microscopy. Platelets reacted strongly with the monoclonal S12 antibody, with an average 22-fold increase in platelet labeling over the negative control IgG. Despite the partial deterioration of platelet structural integrity associated with preservation, labeling was predominantly localized to vacuoles in the platelets that represent the surface-connected canalicular system ( Figure 9 ). Some labeling of the a-granules, while not consistent, was also noted.
Discussion
The present study confirms previous in vitro data showing the high specificity of monoclonal S12 Fab' antibody binding to the a-granule membrane glycoprotein, GMP-140, expressed on the surface of individual platelets.28 Our in vivo and ex vivo imaging data demonstrate that increasingly vigorous and repeated interventional injuries produce a commensurate increase in S12 binding despite angiographic vessel patency. Electron micrographs confirmed extensive acute platelet deposition at atherosclerotic endothelial injury sites in association with immunoelectron microscopic evidence of avid S12 binding to activated platelets. Active neointimal proliferation without platelet activation or significant S12 uptake was observed 1 week after interventional procedures. Despite obvious neointimal proliferation, smooth muscle proliferative changes were minimal at 1 week after PTA in this rabbit model but have been described in humans and pigs at later time after PTA injury.25,37
Previous Imaging Studies
Platelet imaging studies have been used to detect left ventricular thrombus formation,24 in peripheral arteries after angioplasty,22,23 and in coronary artery thrombi. The presence of high nonspecific blood pool background activity due to circulating inactivated platelets has necessitated either dual-tracer subtraction techniques, which are sensitive to motion artifact, or reliance on delayed imaging studies of long half-life radioisotopes (e.g., indium-l 1 and E . S r g o l y 1 wk ar pc u s as p n r FIGURE 7. Silver staining optical microscopyl1week afterpercutaneous transluminal angioplastyplus stent placement reveals that stent struts are covered by a translucent coating of neointima.
iodine-123) to permit thrombus visualization after clearance of blood pooi activity. The monoclonal antibodies 7E3 and P256, which are specific for platelet surface membrane glycoprotein lib-lIIa, have been used for in vivo imaging of deepvein thrombosis with '231-labeled 7E338 and canine vascular thrombus using`In-labeled P256 antibody. 39 Another monoclonal antibody within this cluster of differentiation with specificity for translocated a-granule membrane protein of activated platelets, anti-PADGEM, has been labeled with 1231 for detection of deep venous thrombosis in a baboon model. 31 The imaging advantages identified in this study included low blood pool activity and rapid blood pool clearance (a V/2, 2-6 minutes;: tl/2, 4 hours). In this model venous thrombus was discernible at 15 minutes after injection, with 2-hour target-to-background ratios comparable to those in the present study (averaging 3: 1 in vivo).
Sl2 monoclonal antibody exhibits high in vitro specificity (50:1) for thrombin-stimulated degranulating platelets.27328A(4 Our immunoelectron microscopic studies of post-PTA thrombi confirmed the high in vivo specificity of S12 for activated platelet a-granule GMP-140 (22: 1) compared with nonrelevant antibodies. Lower-level binding of S12 to vascular endothelial GMP-140 in the Weibel-Palade bodies containing von Willebrand factor33 may have accounted for minimal binding of S12 Fab in atherosclerotic uninjured arterial segments.
Clinical Implications
The S12 monoclonal antibody used in the present study is reactive with human platelets. Phase I clinical trials are under way to evaluate S12 uptake in patients injected intravenously and imaged at 1. 4 . and 24 hours after coronary and peripheral vessel angioplasty and amputation for severe arterial insufficiency. These preliminary studies indicate that the initial (4-6-hour) injury ratio and the duration of S12 image-derived platelet activity (less than 24 hours versus more than 24 hours) correlate with the presence of dissection and greater residual stenosis (i.e., turbulence) at PTA sites. 41 The mean values in the unfed control group (1.09+0.13) and the cholesterol-fed control group (1.18+0.13) did not differ significantly from each other and did not equal 1.0 due to the presence of regionally variable secondary counts in the control aortas. For these control groups, the mean+1 SD values were 1.22 and 1.31, respectively. If the value of 1.3 is considered the upper limit of normal, this test would have an 86% specificity and sensitivity in the control, PTA twice, and PTA plus stent subgroups. Using a 2 SD above the control group mean (1.4) as the upper limit of normality, four of seven (57%) of the PTA twice and five of Immunoelectron microscopic study ofplatelets extracted fom an angioplasty injury site reacted with S12 monoclonal antibody (left panel) and nonrelevant antibody (right panel). There is predominant S12 labeling with electron-dense colloidal gold particles at the vacuolated regions of the activated platelets, representing the platelet surface-connected canalicular system expression of GMP-140 originating in the a-granules (bottom). A negative control using the mouse preimmunized sera showing the same platelets sectioned at a different level without any significant labeling (magnification, x61,000). Minimal amounts of extracellular labeling represents membraneous platelet debris included in the clot. seven (71%) of the PTA plus stent studies exceeded this cutoff, for an overall sensitivity of 64% and specificity of 93% in these four groups (n=28). The separation between "normal" and elevated S12 activity ratios in vivo provides diagnostic accuracy that is comparable to that of other antibody-imaging techniques, with acceptable specificity. High initial blood pool activity and individual variability of tracer uptake at injury sites have also been encountered in preliminary clinical studies with this agent.
In our acute in vivo animal studies, platelet-rich thrombi were detected in stents with expanded dimensions of 3 x 5 mm using a standard planar gamma camera. The greater S12 injury ratios observed in excised aortas demonstrate that removal of free 99mTc by manual blood pool subtraction improved localization of S12 uptake compared with 1-hour in vivo images. Based on preliminary clinical studies4' showing clearance of blood pool activity by 4-6 hours after S12 injection and animal studies that demonstrate that only 6+2% of the originally injected dose per gram of blood remains at 6 hours after injection,42 the calculated (decay-corrected) percent of injection dose available in blood is 17% at 6 hours.
Incorporation of the 99mTc label onto S12 Fab' averages 96% at 1 hour of incubation time, after which the labeling efficiency (in human plasma at 37°C) averages 89% at 24 hours (data on file. Centocor, Inc., Malvern, Pa.). Variability in S12 uptake in unheparinized subgroups or rabbits under carefully controlled experimental conditions and heparinized patients after PTA41 suggests that individual characteristics may also influence S12 binding.
Cyclooxygenase inhibitors that are effective in acute thrombosis do not effectively block platelet a-granule secretion43 and do not prevent restenosis after angioplasty.15 Clinicopathological and experimental studies clearly implicate exuberant neointimal smooth muscle proliferation mediated by local platelet-derived growth factor release as the etiology of post-PTA restenosis.7417-19,21 The cellular event detected by these S12 studies is platelet activation and secretion of stored a-granule proteins, including growth factors,27,28 a process distinct from that causing acute vessel closure. 7 The clinical usefulness of in vivo 99mTc S12 imaging for localization of interventional injury sites is implied but remains unproven. S12 Fab' imaging may assist in the prospective evaluation of PTA and other interventional therapies by identifying patients with greater acute platelet degranulization and local growth factor release who are at higher risk of restenosis and in need of more aggressive pharmacotherapy and angiographic follow-up.
